# US 2026/0256640 A1 · Systems and methods to treat retinal degeneration disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0256640 A1
- Document ID: US20260256640A1
- Status: Published application
- Kind: A1
- Application number: 19/165,433
- Filed: 2024-03-13
- Published: 2026-09-03
- Earliest claimed: 2023-03-14
- Assignees: Dandelion Science Corp.
- Applicants: Dandelion Science Corp.
- Inventors: Adam HANINA; Ajay VERMA; Gopal K. CHOPRA; Dan NEMRODOV; Ekaterina MALAKHOVA
- Web page: https://patentgrep.com/patent/US20260256640A1

## CPC

- A61H 5/00: Exercisers for the eyes
- G16H 20/40: relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
- A61H 2201/10: with further special therapeutic means, e.g. electrotherapy, magneto therapy or radiation therapy, chromo therapy, infrared or ultraviolet therapy
- A61H 2201/5007: computer controlled
- A61H 2201/501: connected to external computer devices or networks
- A61H 2201/5043: Displays
- A61H 2201/5097: wireless
- A61H: PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY (electrotherapy, magnetotherapy, radiation therapy or ultrasound therapy A61N)
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

Systems and methods for treating eye disorders, such as retinal degeneration disorders, are disclosed. Adapted visual neuromodulatory codes are retrieved. The adapted visual neuromodulatory codes are adapted to produce neuromodulatory responses in the visual cortex. The adapted visual neuromodulatory codes are output to an electronic display of a device viewable by a patient.

## Claims

### Claim 1

A method for treating eye disorders, comprising:
retrieving one or more adapted visual neuromodulatory codes, said one or more adapted visual neuromodulatory codes being adapted to produce neuromodulatory responses in the visual cortex; and
outputting to an electronic display of a device viewable by a patient said one or more adapted visual neuromodulatory codes.

### Claim 2 (depends on 1)

The method of claim 1, wherein said one or more adapted visual neuromodulatory codes are adapted to improve processing of visual information in a target neural area.

### Claim 3 (depends on 1)

The method of claim 1, wherein said one or more adapted visual neuromodulatory codes are adapted to improve processing of visual information in an intact peripheral visual field.

### Claim 4 (depends on 3)

The method of claim 3, further comprising performing drug therapy to slow progression of a disorder and/or improve visual function, wherein the drug therapy is designed to reduce growth of abnormal blood vessels and leakage of fluid in the macula.

### Claim 5 (depends on 4)

The method of claim 4, wherein wherein the drug therapy comprises anti-vascular endothelial growth factor (VEGF) agents.

### Claim 6 (depends on 1)

The method of claim 1, wherein said one or more adapted visual neuromodulatory codes are generated by:
analyzing a first set of brain activity data to produce at least one parameter indicative of an effectiveness of a candidate dynamic visual neuromodulatory code with respect to a participant;
performing, based at least in part on the at least one parameter indicative of an effectiveness of the candidate dynamic visual neuromodulatory code, one of:
(i) outputting the candidate dynamic visual neuromodulatory code as an adapted dynamic visual neuromodulatory code; and
(ii) perturbing the candidate dynamic visual neuromodulatory code, displaying to the participant the perturbed candidate dynamic visual neuromodulatory code, receiving a second set of brain activity data measured during the displaying to the participant the perturbed candidate dynamic visual neuromodulatory code, and iteratively repeating said analyzing using the second set of brain activity data to produce at least one parameter indicative of an effectiveness of the candidate dynamic visual neuromodulatory code with respect to the participant.

### Claim 7 (depends on 6)

The method of claim 6, wherein said perturbing comprises obtaining a further candidate dynamic visual neuromodulatory code from a machine learning model trained to target specific neural circuits of the visual cortex to treat retinal degeneration disorders.

### Claim 8 (depends on 7)

The method of claim 7, wherein training of the machine learning model comprises
displaying dynamic visual neuromodulatory codes to subjects with different types of retinal degeneration disorders; and
measuring neural responses from the subjects during said displaying.

### Claim at position 9

9-37. (canceled)

### Claim 38

A system for treating eye disorders, comprising:
a device having one or more processors in communication with a memory, the memory storing instructions executable by said one or more processors to perform:
retrieving one or more adapted visual neuromodulatory codes, said one or more adapted visual neuromodulatory codes being adapted to produce neuromodulatory responses in the visual cortex; and
outputting to an electronic display of the device viewable by a patient said one or more adapted visual neuromodulatory codes.

### Claim 39 (depends on 38)

The system of claim 38, wherein said one or more adapted visual neuromodulatory codes are adapted to improve processing of visual information in an intact peripheral visual field.

### Claim 40 (depends on 39)

The system of claim 39, further comprising performing drug therapy to slow progression of a disorder and/or improve visual function, wherein the drug therapy is designed to reduce growth of abnormal blood vessels and leakage of fluid in the macula.

### Claim 41 (depends on 40)

The system of claim 40, wherein the drug therapy comprises anti-vascular endothelial growth factor (VEGF) agents.

### Claim 42 (depends on 38)

The system of claim 38, wherein said one or more adapted visual neuromodulatory codes are generated by:
analyzing a first set of brain activity data to produce at least one parameter indicative of an effectiveness of a candidate dynamic visual neuromodulatory code with respect to a participant;
performing, based at least in part on the at least one parameter indicative of an effectiveness of the candidate dynamic visual neuromodulatory code, one of:
(i) outputting the candidate dynamic visual neuromodulatory code as an adapted dynamic visual neuromodulatory code; and
(ii) perturbing the candidate dynamic visual neuromodulatory code, displaying to the participant the perturbed candidate dynamic visual neuromodulatory code, receiving a second set of brain activity data measured during the displaying to the participant the perturbed candidate dynamic visual neuromodulatory code, and iteratively repeating said analyzing using the second set of brain activity data to produce at least one parameter indicative of an effectiveness of the candidate dynamic visual neuromodulatory code with respect to the participant.

### Claim 43 (depends on 42)

The system of claim 42, wherein said perturbing comprises obtaining a further candidate dynamic visual neuromodulatory code from a machine learning model trained to target specific neural circuits of the visual cortex to treat retinal degeneration disorders.

### Claim 44 (depends on 43)

The system of claim 43, wherein training of the machine learning model comprises
displaying dynamic visual neuromodulatory codes to subjects with different types of retinal degeneration disorders; and
measuring neural responses from the subjects during said displaying.

### Claim 45

A non-transitory computer-readable medium storing instructions that, when executed by one or more processors of a device, cause said one or more processors to perform a method for treating eye disorders, the method comprising
retrieving one or more adapted visual neuromodulatory codes, said one or more adapted visual neuromodulatory codes being adapted to produce neuromodulatory responses in the visual cortex; and
outputting to an electronic display of the device viewable by a patient said one or more adapted visual neuromodulatory codes.

### Claim 46 (depends on 45)

The computer-readable medium of claim 45, wherein said one or more adapted visual neuromodulatory codes are adapted to improve processing of visual information in an intact peripheral visual field.

### Claim 47 (depends on 46)

The computer-readable medium of claim 46, further comprising performing drug therapy to slow progression of a disorder and/or improve visual function, wherein the drug therapy is designed to reduce growth of abnormal blood vessels and leakage of fluid in the macula.

### Claim 48 (depends on 47)

The computer-readable medium of claim 47, wherein the drug therapy comprises anti-vascular endothelial growth factor (VEGF) agents.

### Claim 49 (depends on 45)

The computer-readable medium of claim 45, wherein said one or more adapted visual neuromodulatory codes are generated by:
analyzing a first set of brain activity data to produce at least one parameter indicative of an effectiveness of a candidate dynamic visual neuromodulatory code with respect to a participant;
performing, based at least in part on the at least one parameter indicative of an effectiveness of the candidate dynamic visual neuromodulatory code, one of:
(i) outputting the candidate dynamic visual neuromodulatory code as an adapted dynamic visual neuromodulatory code; and
(ii) perturbing the candidate dynamic visual neuromodulatory code, displaying to the participant the perturbed candidate dynamic visual neuromodulatory code, receiving a second set of brain activity data measured during the displaying to the participant the perturbed candidate dynamic visual neuromodulatory code, and iteratively repeating said analyzing using the second set of brain activity data to produce at least one parameter indicative of an effectiveness of the candidate dynamic visual neuromodulatory code with respect to the participant.

### Claim 50 (depends on 49)

The computer-readable medium of claim 49, wherein said perturbing comprises obtaining a further candidate dynamic visual neuromodulatory code from a machine learning model trained to target specific neural circuits of the visual cortex to treat retinal degeneration disorders.

### Claim 51 (depends on 50)

The computer-readable medium of claim 50, wherein training of the machine learning model comprises
displaying dynamic visual neuromodulatory codes to subjects with different types of retinal degeneration disorders; and
measuring neural responses from the subjects during said displaying.
